Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.50 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180689 | 0.91 | L3MBTL1 (0.61) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL7385615 | 0.89 | CA1 (0.54) | TPSAB1L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL184953 | 0.88 | GLS (0.54) | L3MBTL1NAMPTCA1CYP1A2CYP2D6 | |
| SCHEMBL23568933 | 0.87 | CA1 (0.56) | TPSAB1L3MBTL1GAANAMPTCA1 | |
| SCHEMBL8138303 | 0.87 | L3MBTL1 (0.52) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL30905374 | 0.87 | L3MBTL1 (0.54) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL54834 | 0.87 | EPHX2 (0.55) | L3MBTL1GAANAMPTCA1CA2 | |
| SCHEMBL27113191 | 0.87 | KDM4A (0.46) | TPSAB1L3MBTL1GAANAMPTCA1 | |
| Hydrochloric Acid SCHEMBL31609012 | 0.86 | GLS (0.53) | L3MBTL1NAMPTCA1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL23270117 | 0.86 | L3MBTL1 (0.51) | L3MBTL1GAANAMPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | claimed |
| CN-118561775-A | Preparation method of novel tetralactam macrocyclic rotaxane | 上海大学 | 2024-08-30 | — | — | CN | claimed |
| US-11677123-B2 | Mitigating thermal runaway in lithium ion batteries using damage-initiating materials or devices | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-13 | — | — | US | claimed |
| US-10254291-B2 | Quaternary ammonium containing isobaric tag for quantitative glycan profiling | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2019-04-09 | — | — | US | claimed |
| US-20160252518-A1 | QUATERNARY AMINE CONTAINING ISOBARIC TAG FOR QUANTITATIVE GLYCAN PROFILING | THE JOHNS HOPKINS UNIVERSITY | 2016-09-01 | — | — | US | claimed |
| US-12617905-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| EP-4724442-A1 | AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF | Council of Scientific and Industrial Research (IN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260097137-A1 | FLUORESCENT PROBE COMPOUNDS FOR TUMOR TARGETING IMAGING, AND SYNTHESIS METHOD THEREFOR | HEBEI MEDICAL UNIVERSITY (CN) | 2026-04-09 | — | — | US | disclosed |
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-0674623-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
| CN-1094718-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | CN | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| US-4624943-A | Aromatic basic-tailed vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0195673-A2 | Aromatic basic-tailed vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097137-A1 | FLUORESCENT PROBE COMPOUNDS FOR TUMOR TARGETING IMAGING, AND SYNTHESIS METHOD THEREFOR | SLC7A1, SLC7A11, FOLR2 | TPSAB1 2116/4885L3MBTL1 1813/4885GAA 4734/4885 |
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | EEF1A2, EEF1E1, EEF1D | TPSAB1 2093/4885L3MBTL1 201/4885GAA 2650/4885 |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | TPSAB1 51/4885L3MBTL1 3489/4885GAA 3905/4885 |
| US-12617905-B2 | Crosslinked alginic acid | ALG1, ANXA6, HEXB | TPSAB1 251/4885L3MBTL1 122/4885GAA 1517/4885 |
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | TPSAB1 1620/4885L3MBTL1 3485/4885GAA 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.